Cargando…

Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies

Adeno-associated virus (AAV) delivery of potent and broadly neutralizing antibodies (bNAbs is a promising approach for the prevention of HIV-1 infection. The immunoglobulin G (IgG)1 subtype is usually selected for this application, because it efficiently mediates antibody effector functions and has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gardner, Matthew R., Fetzer, Ina, Kattenhorn, Lisa M., Davis-Gardner, Meredith E., Zhou, Amber S., Alfant, Barnett, Weber, Jesse A., Kondur, Hema R., Martinez-Navio, Jose M., Fuchs, Sebastian P., Desrosiers, Ronald C., Gao, Guangping, Lifson, Jeffrey D., Farzan, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6403482/ https://www.ncbi.nlm.nih.gov/pubmed/30704961 http://dx.doi.org/10.1016/j.ymthe.2019.01.004

Ejemplares similares

AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity
por: Fuchs, Sebastian P., et al.
Publicado: (2015)

Glycoengineering of AAV-delivered monoclonal antibodies yields increased ADCC activity
por: Termini, James M., et al.
Publicado: (2020)

Long-Term Delivery of an Anti-SIV Monoclonal Antibody With AAV
por: Martinez-Navio, José M., et al.
Publicado: (2020)

High concordance of ELISA and neutralization assays allows for the detection of antibodies to individual AAV serotypes
por: Gardner, Matthew R., et al.
Publicado: (2022)

A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies
por: Davis-Gardner, Meredith E., et al.
Publicado: (2020)

Liver-Directed but Not Muscle-Directed AAV-Antibody Gene Transfer Limits Humoral Immune Responses in Rhesus Monkeys
por: Fuchs, Sebastian P., et al.
Publicado: (2019)

Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies
por: Otsuka, Yuka, et al.
Publicado: (2018)

Recombinant AAV Vectors for Enhanced Expression of Authentic IgG
por: Fuchs, Sebastian P., et al.
Publicado: (2016)

A strategy for high antibody expression with low anti-drug antibodies using AAV9 vectors
por: Davis-Gardner, Meredith E., et al.
Publicado: (2023)

eCD4-Ig promotes ADCC activity of sera from HIV-1-infected patients
por: Davis-Gardner, Meredith E., et al.
Publicado: (2017)

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges
por: Gardner, Matthew R., et al.
Publicado: (2015)

Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies
por: Fuchs, Sebastian P, et al.
Publicado: (2016)

Editorial: “AAV Gene Therapy: Immunology and Immunotherapeutics”
por: Martinez-Navio, José M., et al.
Publicado: (2021)

Effective Depletion of Pre-existing Anti-AAV Antibodies Requires Broad Immune Targeting
por: Velazquez, Victoria M., et al.
Publicado: (2017)

rAAV expressing recombinant neutralizing antibody for the botulinum neurotoxin type A prophylaxis
por: Derkaev, Artem A., et al.
Publicado: (2022)

rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19
por: Esmagambetov, Ilias B., et al.
Publicado: (2023)

Engineering antibody-like inhibitors to prevent and treat HIV-1 infection
por: Gardner, Matthew R., et al.
Publicado: (2017)

Development of broad‐spectrum human monoclonal antibodies for rabies post‐exposure prophylaxis
por: De Benedictis, Paola, et al.
Publicado: (2016)

Antiviral mechanisms of two broad-spectrum monoclonal antibodies for rabies prophylaxis and therapy
por: Zorzan, Maira, et al.
Publicado: (2023)

A broad-spectrum and highly potent human monoclonal antibody cocktail for rabies prophylaxis
por: Kim, Pan Kyeom, et al.
Publicado: (2021)

Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible Solutions
por: Weber, Thomas
Publicado: (2021)

AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region
por: van den Berg, Fiona T., et al.
Publicado: (2019)

1231. VIR-2482: A potent and broadly neutralizing antibody for the prophylaxis of influenza A illness
por: Pizzuto, Matteo Samuele, et al.
Publicado: (2020)

rAAV-delivered PTEN therapeutics for prostate cancer
por: Ai, Jianzhong, et al.
Publicado: (2021)

Mapping the complete glycoproteome of virion-derived HIV-1 gp120 provides insights into broadly neutralizing antibody binding
por: Panico, Maria, et al.
Publicado: (2016)

Successful Transduction with AAV Vectors after Selective Depletion of Anti-AAV Antibodies by Immunoadsorption
por: Orlowski, Alejandro, et al.
Publicado: (2020)

Cost‐effectiveness of broadly neutralizing antibody prophylaxis for HIV‐exposed infants in sub‐Saharan African settings
por: Dugdale, Caitlin M., et al.
Publicado: (2023)

Contribution to HIV Prevention and Treatment by Antibody-Mediated Effector Function and Advances in Broadly Neutralizing Antibody Delivery by Vectored Immunoprophylaxis
por: Phelps, Meredith, et al.
Publicado: (2021)

Stabilization of a Broadly Neutralizing Anti-Chikungunya Virus Single Domain Antibody
por: Liu, Jinny L., et al.
Publicado: (2021)

A Small Virus to Deliver Small Antibodies: New Targeted Therapies Based on AAV Delivery of Nanobodies
por: Silva-Pilipich, Noelia, et al.
Publicado: (2021)

Broadly Neutralizing Antibodies for HIV Eradication
por: Stephenson, Kathryn E., et al.
Publicado: (2016)

Tackling influenza with broadly neutralizing antibodies
por: Corti, Davide, et al.
Publicado: (2017)

Role of framework mutations and antibody flexibility in the evolution of broadly neutralizing antibodies
por: Ovchinnikov, Victor, et al.
Publicado: (2018)

The use of antibodies in the prophylaxis and treatment of infections
por: Lachmann, Peter J
Publicado: (2012)

Estimation of the in vivo neutralization potency of eCD4Ig and conditions for AAV-mediated production for SHIV long-term remission
por: Goyal, Ashish, et al.
Publicado: (2022)

Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis (AAV) Restricted to the Limbs
por: Ojima, Yoshie, et al.
Publicado: (2017)

Rapid AAV-Neutralizing Antibody Determination with a Cell-Binding Assay
por: Guo, Ping, et al.
Publicado: (2018)

Global CNS Gene Delivery and Evasion of Anti-AAV Neutralizing Antibodies by Intrathecal AAV Administration in Non-Human Primates
por: Gray, Steven J., et al.
Publicado: (2013)

Cost-effectiveness of broadly neutralizing antibodies for infant HIV prophylaxis in settings with high HIV burdens: a simulation modeling study
por: Alba, Christopher, et al.
Publicado: (2023)

Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development
por: Wiehe, Kevin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1b4hp3g1bgekmmcf0h1aof2kg8